Analyses of C-Reactive Protein, Endothelial Nitric Oxide Synthase and Interleukin-6 Gene Polymorphisms in Adolescents with a Family History of Premature Coronary Artery Disease: A Pilot Study

Abstract

Background: Family history of premature atherosclerosis imposes a high risk to people. The relationship between atherosclerosis and gene polymorphisms of various biomarkers such as Endothelial Nitric Oxide Synthase (eNOS), C-Reactive Protein (CRP), and Interleukin-6 (IL-6) has shown in previous studies. Aims: The major aim of the study was to evaluate the CRP, eNOS, and IL-6 gene polymorphisms in a group of adolescents who have a parental history of early coronary artery disease (CAD). Study Design: Case-control study. Methods: Thirty-six volunteers with a father with obstructive CAD during the first four decades and 46 subjects with a father with normal coronary arteries documented with coronary angiography were included in the study. Polymerase chain reaction-restriction fragment length polymorphism techniques were used to analyze CRP, eNOS, and IL-6 polymorphisms. Results: We did not find any differences between the two groups with regard to age, sex, body mass index, renal functions, systolic and diastolic blood pressures, lipid profile, and fasting glucose, hemoglobin, and high sensitivity CRP. A significant difference was only observed in IL-6-572 G/C genotype distribution and allele frequency between two groups (Pc=0.036 OR=3.48 CI (95%) 1.17-10.32). Conclusion: The present study showed a significant association between the IL-6-572 G/C gene polymorphism (presence of C allele) and adolescents with a parental history of premature CAD.

Keywords

• Atherosclerosis, C-reactive protein, polymorphism, nitric oxide synthase, interleukins

References

1. 1. Najjar SS, Scuteri A, Lakatta EG. Arterial aging: is it an immutable cardiovascular risk factor? Hypertension 2005;46:454-62. [CrossRef]
2. 2. Stary HC. Evolution and progression of atherosclerotic lesions in coronary arteries of children and young adults. Arteriosclerosis 1989;9:I19-32.
3. 3. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, et al; European Society of Cardiology Committee for Practice Guidelines. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003;24:1601- 10. [CrossRef]
4. 4. Virani SS, Polsani VR, Nambi V. Novel markers of inflammation in atherosclerosis. Curr Atheroscler Rep 2008;10:164-70. [CrossRef]
5. 5. Kampoli AM, Tousoulis D, Antoniades C, Siasos G, Stefanadis C. Biomarkers of premature atherosclerosis. Trends Mol Med 2009;15:23-32. [CrossRef]
6. 6. Tousoulis D, Kampoli AM, Papageorgiou N, Androulakis E, Antoniades C, Toutouzas K, et al. Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des 2011;17:4089- 110. [CrossRef]
7. 7. Mani A, Radhakrishnan J, Wang H, Mani A, Mani MA, NelsonWilliams C, et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 2007;315:1278-82. [CrossRef]
8. 8. Mayer B, Erdmann J, Schunkert H. Genetics and heritability of coronary artery disease and myocardial infarction. Clin Res Cardiol 2007;96:1-7. [CrossRef]

9. 9. Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, et al; for the American Heart Association Atherosclerosis, Hypertension and Obesity in Youth Committee of the Council on Cardiovascular Disease in the Young. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: recommendations for standard assessment for clinical research: a scientific statement from the American Heart Association. Hypertension 2009;54:919-50. [CrossRef]
10. 10. Celik A, Ozcetin M, Celikyay ZR, Sogut E, Yerli Y, Kadi H, et al. Evaluation of possible subclinical atherosclerosis in adolescents with a family history of premature atherosclerosis. Atherosclerosis 2012;222:537-40. [CrossRef]
11. 11. McDade TW, Hawkley LC, Cacioppo JT. Psychological and behavioral predictors of inflammation in middle-aged and older adults: The Chicago Health, Aging, and Social Relations Study. Psychosom Med 2006;68:376-81. [CrossRef]
12. 12. Andresdottir MB, Sigurdsson G, Sigvaldason H, Gudnason V. Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study. Eur Heart J 2002;23:1655-63. [CrossRef]
13. 13. Ciftdogan DY, Coskun S, Ulman C, Tikiz H. The factor V G1691A, factor V H1299R, prothrombin G20210A polymorphisms in children with family history of premature coronary artery disease. Coron Artery Dis 2009;20:435-9. [CrossRef]
14. 14. Yan M, Zhao L, Zheng F, Sun X, Zhang Y, Wang C. The relationship between gene polymorphism and CRP level in a Chinese Han population. Biochem Genet 2007;45:1-9. [CrossRef]
15. 15. Brull DJ, Serrano N, Zito F, Jones L, Montgomery HE, Rumley A, et al. Human CRP gene polymorphism influences CRP levels: implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003;23:2063-9. [CrossRef]
16. 16. Wang L, Lu X, Li Y, Li H, Chen S, Gu D. Functional analysis of the C-reactive protein (CRP) gene -717A>G polymorphism associated with coronary heart disease. BMC Med Genet 2009;10:73. [CrossRef]
17. 17. Akbarzadeh Najar R, Ghaderian SM, Tabatabaei Panah AS. Creactive protein(CRP) gene polymorphisms: implication in CRP plasma levels and susceptibility to acute myocardial infarction. Mol Biol Rep 2012;39:3705-12. [CrossRef]
18. 18. Hermann M, Fischer D, Hoffmann MM, Gasser T, Quitzau K, Meinertz T, et al. CRP and CD14 polymorphisms correlate with coronary plaque volume in patients with coronary artery disease--IVUS substudy of the ENCORE trials. Atherosclerosis 2012;220:172-6. [CrossRef]
19. 19. Abd El-Aziz TA, Mohamed RH. Human C-reactive protein gene polymorphism and metabolic syndrome are associated with premature coronary artery disease. Gene 2013;532:216-21. [CrossRef]
20. 20. Giacconi R, Cipriano C, Albanese F, Boccoli G, Saba V, Olivieri F, et al. The 174G/C polymorphism of IL-6 is useful to screen old subjects at risk for atherosclerosis or to reach successful ageing. Exp Gerontol 2004;39:621-8. [CrossRef]
21. 21. Brull DJ, Montgomery HE, Sanders J, Dhamrait S, Luong L, Rumley A, et al. Interleukin-6 gene -174G/C and -572G/C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001;21:1458-63. [CrossRef